{"id":"NCT00655486","sponsor":"UCB BIOSCIENCES, Inc.","briefTitle":"Study to Assess the Long-term Safety of Oral Lacosamide in Subjects With Partial-onset Seizures","officialTitle":"A Multicenter, Open-label Extension Trial to Assess the Long-term Safety and Tolerability of Lacosamide as Adjunctive Therapy in Subjects With Partial-onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2010-06","completion":"2010-06","firstPosted":"2008-04-10","resultsPosted":"2011-07-15","lastUpdate":"2018-07-17"},"enrollment":97,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Partial Epilepsies","Partial Onset Seizures"],"interventions":[{"type":"DRUG","name":"lacosamide","otherNames":["Vimpat"]}],"arms":[{"label":"Lacosamide","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to allow eligible subjects from the parent study, SP925 \\[NCT00655551\\] to continue lacosamide and to obtain additional long-term safety data","primaryOutcome":{"measure":"Number of Subjects With at Least One Adverse Event During This Open-label Extension Study (Maximum Study Duration 2 Years)","timeFrame":"2 years","effectByArm":[{"arm":"Lacosamide","deltaMin":93,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":97},"commonTop":["Dizziness","Diplopia","Vomiting","Upper respiratory tract infection","Nausea"]}}